A 52-year-old man with diabetes mellitus presents with fever, dysuria, and flank pain. Urine culture grows an ESBL-producing Escherichia coli. The organism is susceptible to cephalosporins on disk diffusion but resistant on ESBL confirmatory testing. What is the drug of choice for this upper urinary tract infection?

Explanation

## ESBL-Producing Gram-Negative Bacteria: Treatment Principles **Key Point:** ESBL-producing organisms are resistant to all β-lactams except carbapenems, despite appearing susceptible on routine disk diffusion testing. This is a critical distinction in clinical practice. ### Why Carbapenems Are First-Line **High-Yield:** Carbapenems (meropenem, imipenem, ertapenem) are the only β-lactam class reliably effective against ESBL producers because: 1. Their β-lactam ring structure is resistant to hydrolysis by extended-spectrum β-lactamases 2. They have superior penetration into renal tissue and urine 3. They achieve bactericidal concentrations in the urinary tract ### ESBL Confirmatory Testing Interpretation When an organism shows: - **Susceptible** on routine cephalosporin disk diffusion (e.g., ceftriaxone MIC ≤1 µg/mL) - **Resistant** on ESBL confirmatory test (cephalosporin + clavulanic acid showing ≥3 mm zone increase) This confirms ESBL production, and **clinical failures occur with all cephalosporins**, regardless of in vitro appearance. ### Drug Comparison for ESBL-Producing UTI | Drug | Mechanism | Efficacy in ESBL | Urinary Penetration | Use | |------|-----------|------------------|---------------------|-----| | Meropenem | Carbapenem; β-lactamase resistant | Excellent | Excellent | **First-line** | | Ceftriaxone | 3rd-gen cephalosporin; ESBL substrate | Poor (clinical failure) | Good | Contraindicated | | Cefixime | 3rd-gen cephalosporin; ESBL substrate | Poor (clinical failure) | Moderate | Contraindicated | | Fluoroquinolone | DNA gyrase inhibitor; non-β-lactam | Moderate | Excellent | Alternative if carbapenem unavailable | **Clinical Pearl:** The paradox of ESBL organisms is that they may appear susceptible on automated systems or disk diffusion but will clinically fail with cephalosporins. ESBL confirmatory testing (double-disk synergy or Etest) is mandatory before reporting susceptibility. **Warning:** Never use ceftriaxone, cefixime, or other cephalosporins for confirmed ESBL producers, even if the organism appears susceptible on initial screening. Clinical failures and treatment complications are well-documented. ### Meropenem in This Case Meropenem is preferred over imipenem for UTI because: - Better renal penetration - Lower seizure risk (imipenem is more neurotoxic) - Excellent activity against ESBL-producing E. coli - Dose: 500 mg IV 8-hourly for upper UTI **Mnemonic:** **ESBL = Exclude all cephalosporins, use Carbapenem** (or fluoroquinolone as backup)